What is 9 Meters Biopharma, Inc. (NMTRQ)?

9 Meters Biopharma, Inc. (NMTRQ) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of NMTRQ?

The current price of NMTRQ is $0.00. Prices are updated in real time on Stocks360.

What is NMTRQ's market capitalization?

NMTRQ's market capitalization is $1,446.00, placing it in the small-cap tier.

9 Meters Biopharma, Inc. (NMTRQ)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$1.45K

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

8.28

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

5.96K

9 Meters Biopharma, Inc. (NMTRQ) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $1.45K. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $0.00 2026-10-27 · $0.00 (+9900.00%)

Earnings

Most Recent

May 15, 2023

EPS $-1.02 vs est. $-0.69

Missed by $0.33

Next Earnings

Nov 11, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About 9 Meters Biopharma, Inc.

Operating as a clinical-stage biopharmaceutical firm, 9 Meters Biopharma, Inc. specialized in creating therapies for individuals in North America afflicted by rare digestive illnesses, various gastrointestinal disorders lacking effective treatments, and other debilitating conditions. Its primary therapeutic candidate was Vurolenatide, a long-acting injectable glucagon-like peptide-1, which had advanced to Phase 3 clinical trials for the management of short bowel syndrome. The company's pipeline also included NM-136, a humanized monoclonal antibody aimed at treating obesity and associated conditions; NM-102, a small molecule peptide designed to hinder antigen entry into the systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended to prevent acute graft versus host disease. Furthermore, it partnered on Larazotide, an 8-amino acid peptide undergoing Phase 2 clinical trials for multi-system inflammatory syndrome. Licensing arrangements were established with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, 9 Meters Biopharma, Inc. initiated a voluntary petition for l…